<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>MMSI Stock Falls Despite CE Mark Win for Embosphere in Knee OA Care</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>MMSI Stock Falls Despite CE Mark Win for Embosphere in Knee OA Care</h1>
  <ul>
<li>West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%.</li>
<li>Medpace Holdings, sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%.</li>
<li>Revenues of $603.3 million outpaced the consensus mark by 11.5%.</li>
<li>Revenues of $682 million surpassed the Zacks Consensus Estimate by 6.3%.</li>
<li>Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%.</li>
<li>Envista reported second-quarter 2025 adjusted EPS of 26 cents, which beat the Zacks Consensus Estimate by 8.3%.</li>
<li>Favorable Industry Prospects for MMSI Per a report by Grand View Research, the global osteoarthritis therapeutics market size was estimated at $9.13 billion in 2024 and is projected to reach $13.57 billion by 2030, regis</li>
</ul>
<p><a href="https://finance.yahoo.com/news/mmsi-stock-falls-despite-ce-163400406.html">Source</a> · 2025-09-15T16:34:00+00:00</p>
</body>
</html>